风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请

2018-12-25 MedSci MedSci原创

upadacitinib类风湿性关节炎Abbvie
关注

AbbVie是一家以研究为基础的全球生物制药公司，近日宣布已向美国食品药品管理局（FDA）提交了新药申请（NDA），并向欧洲药品管理局（EMA）提交了上市授权申请（MAA）。Upadacitinib是一种研究性口服型JAK1选择性抑制剂，用于治疗中度至重度类风湿性关节炎的成年患者。

AbbVie是一家以研究为基础的全球生物制药公司，近日宣布已向美国食品药品管理局（FDA）提交了新药申请（NDA），并向欧洲药品管理局（EMA）提交了上市授权申请（MAA）。Upadacitinib是一种研究性口服型JAK1选择性抑制剂，用于治疗中度至重度类风湿性关节炎的成年患者。

AbbVie副主席兼总裁Michael Severino说：“AbbVie致力于为数百万患有类风湿性关节炎的人提供护理服务，这其中许多人仍未达到治疗目标。Upadacitinib如果获得批准，则可能是广泛的类风湿性关节炎患者的一个重要的治疗选择。我们期待在整个审查过程中与监管机构合作”。

全球多中心III期SELECT临床试验为本次NDA和MAA提供了数据支持，SELECT试验评估了4,000多名中度至重度类风湿性关节炎患者。结果显示，Upadacitinib符合所有主要和次要终点。Upadacitinib最常见的严重不良事件是感染。


原始出处：

http://www.firstwordpharma.com/node/1612942#axzz5aJrWexZu

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738539, encodeId=bfdf1e385393a, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Sep 09 14:00:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744179, encodeId=dfd01e44179ac, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Tue Jan 08 05:00:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264678, encodeId=5cd012646e824, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265875, encodeId=ebe212658e5e1, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334100, encodeId=c2421334100ea, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479586, encodeId=0b9b14e958633, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483568, encodeId=b38814835684b, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551424, encodeId=d6fa1551424ab, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
    2019-09-09 12498877m109暂无昵称

    #CIT#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1738539, encodeId=bfdf1e385393a, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Sep 09 14:00:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744179, encodeId=dfd01e44179ac, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Tue Jan 08 05:00:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264678, encodeId=5cd012646e824, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265875, encodeId=ebe212658e5e1, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334100, encodeId=c2421334100ea, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479586, encodeId=0b9b14e958633, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483568, encodeId=b38814835684b, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551424, encodeId=d6fa1551424ab, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
    2019-01-08 wangbingxhy

    #新药申请#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1738539, encodeId=bfdf1e385393a, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Sep 09 14:00:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744179, encodeId=dfd01e44179ac, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Tue Jan 08 05:00:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264678, encodeId=5cd012646e824, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265875, encodeId=ebe212658e5e1, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334100, encodeId=c2421334100ea, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479586, encodeId=0b9b14e958633, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483568, encodeId=b38814835684b, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551424, encodeId=d6fa1551424ab, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
    2018-12-27 般若傻瓜

    #ADA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1738539, encodeId=bfdf1e385393a, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Sep 09 14:00:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744179, encodeId=dfd01e44179ac, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Tue Jan 08 05:00:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264678, encodeId=5cd012646e824, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265875, encodeId=ebe212658e5e1, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334100, encodeId=c2421334100ea, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479586, encodeId=0b9b14e958633, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483568, encodeId=b38814835684b, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551424, encodeId=d6fa1551424ab, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
    2018-12-27 lmm397

    #关节炎#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1738539, encodeId=bfdf1e385393a, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Sep 09 14:00:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744179, encodeId=dfd01e44179ac, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Tue Jan 08 05:00:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264678, encodeId=5cd012646e824, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265875, encodeId=ebe212658e5e1, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334100, encodeId=c2421334100ea, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479586, encodeId=0b9b14e958633, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483568, encodeId=b38814835684b, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551424, encodeId=d6fa1551424ab, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
    2018-12-27 ms4964546379600229

    #类风湿#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1738539, encodeId=bfdf1e385393a, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Sep 09 14:00:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744179, encodeId=dfd01e44179ac, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Tue Jan 08 05:00:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264678, encodeId=5cd012646e824, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265875, encodeId=ebe212658e5e1, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334100, encodeId=c2421334100ea, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479586, encodeId=0b9b14e958633, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483568, encodeId=b38814835684b, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551424, encodeId=d6fa1551424ab, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
    2018-12-27 12498768m15(暂无昵称)

    #Abbvie#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1738539, encodeId=bfdf1e385393a, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Sep 09 14:00:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744179, encodeId=dfd01e44179ac, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Tue Jan 08 05:00:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264678, encodeId=5cd012646e824, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265875, encodeId=ebe212658e5e1, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334100, encodeId=c2421334100ea, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479586, encodeId=0b9b14e958633, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483568, encodeId=b38814835684b, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551424, encodeId=d6fa1551424ab, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
    2018-12-27 ms1467340776200723

    #风湿性关节炎#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1738539, encodeId=bfdf1e385393a, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Sep 09 14:00:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744179, encodeId=dfd01e44179ac, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58646, encryptionId=657a58646ca, topicName=新药申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab3c35313981, createdName=wangbingxhy, createdTime=Tue Jan 08 05:00:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264678, encodeId=5cd012646e824, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265875, encodeId=ebe212658e5e1, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334100, encodeId=c2421334100ea, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479586, encodeId=0b9b14e958633, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483568, encodeId=b38814835684b, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551424, encodeId=d6fa1551424ab, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Thu Dec 27 09:00:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
    2018-12-27 10518098zz

    #美国FDA#

    0

相关资讯

艾伯维关节炎新药upadacitinib抵达3期终点 效果优于Humira

艾伯维（AbbVie）公司今日宣布，其3期临床试验SELECT-COMPARE取得积极的顶线结果。结果显示，upadacitinib（每日一次15 mg）在给药12 周后，与安慰剂相比，对类风湿性关节炎患者达到了ACR20的主要终点和临床缓解。与adalimumab (阿达木单抗，Humira®，每隔一周40 mg）或安慰剂相比，达到所有次要终点。

Lancet：Upadacitinib，选择性JAK1抑制剂，可快速改善难治性类风湿关节炎患者症状

Upadacitinib，一种选择性Janus激酶1（JAK1）抑制剂，其相关2期临床试验显示用于治疗活动性类风湿性关节炎患者的效果和安全性良好。现研究人员对upadacitinib用于对生物疾病修饰类抗风湿药物（bDMARDs）反应不充分患者的效果和安全性进行深入评估。研究人员在26个国家的153个地点进行一双盲的、随机对照3期试验，招募年满18岁的既往对bDMARDs治疗低反应或不耐受的、同时